Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
6 hedge funds and large institutions have $1.75M invested in Seelos Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
81% more capital invested
Capital invested by funds: $965K → $1.75M (+$782K)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.47M |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$36.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$564K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$41K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$36.8K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8K |
SEEL Hedge Fund Activity: Q3 2018 in Review
6 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2018, worth a combined $1.75M — up 81% from $965K a quarter earlier.
Fund positioning in SEEL was balanced in Q3 2018: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.47M. The largest seller was Sarissa Capital Management, exiting entirely with an estimated $564K sold.
- 6 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $1.75M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2018, up 81% quarter-over-quarter.
- 2 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2018 and 2 closed out, a net change of 0 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2018 was Armistice Capital, an estimated $1.47M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2018 was Sarissa Capital Management, an estimated $564K sold.
Based on aggregated 13F filings for Q3 2018.